Molecular signature detection of circulating tumor cells using a panel of selected genes

Gervasoni, Annalisa; Muñoz, Rina M. Monasterio; Wengler, Georg S.; Rizzi, Anna; Zaniboni, Alberto; Parolini, Ornella

doi:10.1016/j.canlet.2008.01.003

Cited by 53 publications

(39 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HER-2 positive sera were already reported in the serum of 27 Iranian breast cancer patients with metastasis [19]. The expression of this marker was not significant in our study (p00.181), while Ki67 biomarker expression was highly significant (p00.001).…”

Section: Discussioncontrasting

confidence: 63%

See 1 more Smart Citation

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

A biomarker is a quantifiable laboratory measure of a disease specific biologically relevant molecule that can act as an indicator of a current or future disease state. The purpose of this study is to detect the expression of RNA biomarkers using Cytokeratin 19 (CK-19), Mammaglobin (MAM), Carcinoembryonic antigen (CEA), Mucin (MUC), C-Myc, erb-B2, a proliferation marker (Ki-67), Epidermal growth factor receptor (Her2/neu) and Estrogen receptor (ER) in Iranian women who were diagnosed with breast cancer. In this study, 90 samples; 60 cancer patients and 30 healthy controls were considered. 73.4 % patients were in stage I/II and 26.6 % were in stage III/IV. Patients were selected prior to the administration of any adjuvant systemic therapy. Total RNA extraction was obtained from peripheral blood of each patient and healthy control. Reverse transcription polymerase chain reaction (RT-PCR) method was used for detection of mRNA of the selected biomarkers of circulating breast cancer cells in blood. Molecular characterization is assessed as a method for early detection of breast cancer. For this purpose, eleven specific primers were selected and RT-PCR was used. The data of RT-PCR revealed that expression of MUC1, CK19, CEA, MAM, erbB-2, Ki67 and C-Myc biomarkers were significantly different between breast cancer patients and healthy controls. On the other hand, ERα, ERβ and Her2 markers were not significantly different between the two mentioned groups.

show abstract

Section: Discussioncontrasting

confidence: 63%

“…Circulating tumor cell (CTC) detection in peripheral blood of epithelial cancer patients is a recognized indicator for the presence of primary tumors and/or metastasis [19]. RT-PCR technique has been used in the detection of specific tumor cell markers, thus indicating the presence of circulating breast cancer cells in blood.…”

Section: Introductionmentioning

confidence: 99%

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

show abstract

“…Early attempts to molecularly characterize CTCs in breast cancer patients yielded poor results, primarily because of the small number of CTCs collected and the inevitable contamination by circulating leukocytes. As such, those studies mostly pursued only small numbers of gene candidates that were already known to be involved in breast cancer progression, metastasis and therapeutic resistance, rather than global transcriptional profiles (Aktas et al, 2011;Bolke et al, 2009;Gervasoni et al, 2008;Gradilone et al, 2011;Theodoropoulos et al, 2010). Recent technological advancements allow for immunomagnetic-bead-or microfluidicbased isolation of CTCs (Autebert et al, 2015;Magbanua and Park, 2013).…”

Section: Molecular Profiling Of Circulating Tumor Cellsmentioning

confidence: 99%

Signatures of breast cancer metastasis at a glance

Karagiannis

Goswami

Jones

et al. 2016

Journal of Cell Science

View full text Add to dashboard Cite

Gene expression profiling has yielded expression signatures from which prognostic tests can be derived to facilitate clinical decision making in breast cancer patients. Some of these signatures are based on profiling of whole tumor tissue (tissue signatures), which includes all tumor and stromal cells. Prognostic markers have also been derived from the profiling of metastasizing tumor cells, including circulating tumor cells (CTCs) and migratory–disseminating tumor cells within the primary tumor. The metastasis signatures based on CTCs and migratory–disseminating tumor cells have greater potential for unraveling cell biology insights and mechanistic underpinnings of tumor cell dissemination and metastasis. Of clinical interest is the promise that stratification of patients into high or low metastatic risk, as well as assessing the need for cytotoxic therapy, might be improved if prognostics derived from these two types of signatures are used in a combined way. The aim of this Cell Science at a Glance article and accompanying poster is to navigate through both types of signatures and their derived prognostics, as well as to highlight biological insights and clinical applications that could be derived from them, especially when they are used in combination.

show abstract

“…[16][17][18][19] In addition, we demonstrate for the first time that presurgical serum sE-selectin levels may also behave as a useful prognostic indicator for recurrent CRC. This finding is in agreement with previously published observations indicating that elevated sE-selectin concentration was associated with a bad prognosis for recurrencefree survival and overall survival in patients with lymph node-negative breast cancer, 21 and that E-selectin could be detected on the membranes of peritumoral endothelial cells, but not on breast epithelial cells, using PCR in situ hybridization.…”

Section: Discussionmentioning

confidence: 69%

“…12 Numerous studies have reported the use of RT-PCR technology to detect CEA message in tumor cells from peripheral blood of cancer patients, 13 suggesting that longitudinal analyses of blood-borne cells expressing CEA by RT-PCR may be useful for the clinical management of CRC and other CEA-expressing tumors in terms of prognosis or in the analysis of the response to therapy either alone [14][15][16][17] or in combination with other molecular markers. 18,19 In light of these considerations, a follow-up study of CRC patients was performed to investigate the possible association of presurgical serum sE-selectin levels with the positivity for CEA mRNA by RT-PCR in peripheral blood cells, as well as their prognostic value in predicting recurrence-free survival.…”

mentioning

confidence: 99%

Serum sE‐selectin levels and carcinoembryonic antigen mRNA‐expressing cells in peripheral blood as prognostic factors in colorectal cancer patients

Ferroni

Roselli

Spila

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: This study analyzed the possible prognostic value of presurgical serum soluble (s)E-selectin levels and/or carcinoembryonic antigen (CEA) mRNA positivity in predicting the disease-free survival of colorectal cancer (CRC) patients. METHODS: CEA mRNA (obtained from blood-borne cells by reverse transcriptase-polymerase chain reaction [RT-PCR]), tumor necrosis factor-a (TNF-a), and sE-selectin levels were analyzed in blood samples obtained from 78 patients with primary (n ¼ 62) or recurrent (n ¼ 16) CRC, 40 patients with benign colorectal (CR) diseases, and 78 controls. RESULTS: CEA mRNA positivity by RT-PCR was significantly associated with advanced stage (P < .05). Median baseline sE-selectin levels were higher in patients with CRC (43 ng/mL) compared with controls (36 ng/mL) or patients with benign CR diseases (31 ng/mL, P < .001). These were significantly associated with CEA mRNA positivity by RT-PCR (P < .05). Multivariate analysis by forward stepping showed that elevated TNF-a (P ¼ .001) and CEA mRNA positivity by RT-PCR (P ¼ .0001) were independent predictors of elevated baseline sE-selectin levels. Positive presurgical sE-selectin levels were associated with an increased recurrence rate compared with patients with low levels of this molecule (P < .001). Positivity for both CEA mRNA and sE-selectin had a negative prognostic impact, with a 5-year recurrence-free survival rate of 51% compared with 95% of patients with negative parameters (P < .05). CONCLUSIONS: Detection of presurgical serum sE-selectin levels and CEA mRNA-positive blood-borne cells in CRC patients might provide useful prognostic information in terms of recurrence-free survival, either alone or in combination, and may help in the choice of more aggressive treatment and/or more strict follow-up procedures in high-risk patients.

show abstract

Molecular signature detection of circulating tumor cells using a panel of selected genes

Cited by 53 publications

References 89 publications

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Signatures of breast cancer metastasis at a glance

Serum sE‐selectin levels and carcinoembryonic antigen mRNA‐expressing cells in peripheral blood as prognostic factors in colorectal cancer patients

Contact Info

Product

Resources

About